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Abstract
Background: Maturation of enterocytes along the small intestinal crypt-villus axis is associated with significant
changes in gene expression profiles. fls485 coding a putative chaperone protein has been recently suggested as a
gene involved in this process. The aim of the present study was to analyze fls485 expression in human small
intestinal mucosa.
Methods: fls485 expression in purified normal or intestinal mucosa affected with celiac disease was investigated
with a molecular approach including qRT-PCR, Western blotting, and expression strategies. Molecular data were
corroborated with several in situ techniques and usage of newly synthesized mouse monoclonal antibodies.
Results: fls485 mRNA expression was preferentially found in enterocytes and chromaffine cells of human intestinal
mucosa as well as in several cell lines including Rko, Lovo, and CaCo2 cells. Western blot analysis with our new
anti-fls485 antibodies revealed at least two fls485 proteins. In a functional CaCo2 model, an increase in fls485
expression was paralleled by cellular maturation stage. Immunohistochemistry demonstrated fls485 as a cytosolic
protein with a slightly increasing expression gradient along the crypt-villus axis which was impaired in celiac
disease Marsh IIIa-c.
Conclusions: Expression and synthesis of fls485 are found in surface lining epithelia of normal human intestinal
mucosa and deriving epithelial cell lines. An interdependence of enterocyte differentiation along the crypt-villus
axis and fls485 chaperone activity might be possible.
Background
Sequential expression of genes and translation of the
related molecules are generally assumed as a fundamen-
tal regulatory algorithm in development and cellular dif-
ferentiation. In human small intestine, the crypt-villus
axis (CVA) is one important example for cellular differ-
entiation [1]. Epithelial cells migrate upward and down-
ward the axis starting from the stem cell pools anchored
adjacent to the crypt basis with a migration out of the
crypt onto upper areas. Along the CVA, structural dif-
ferentiation and functional specialization of enterocytes
occur in a few days and are associated with a significant
change in the panel of genes expressed [2]. This cellular
differentiation is highly hampered in celiac disease, a
disorder morphologically characterized by intraepithelial
lymphocytosis, destruction of villi, and hyperplasia of
crypts triggered by ingestion of gluten proteins con-
tained in wheat, barley, and rye [3]. The spectrum of
consecutive morphological changes in mucosal architec-
ture of the small intestine is systematically addressed in
the Marsh classification [4,5]. Evidence is given that glu-
ten affects differentiation-associated genes in enterocytes
[6], confers susceptibility to adenocarcinomas in human
small intestine [7], and is associated with redox imbal-
ance in intestinal mucosa and blood probably due to
overproduction of free radicals [8,9].
Recently, an expression analysis of small intestinal
enterocytes laser microdissected from the CVA was per-
formed using Affymetrix X3P arrays containing 61,359
sequences representing approximately 47,000 transcripts
[10]. In this setting, 415 genes were found
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and one of these was fls485.T h eg e n efls485
(LOC51006; C3orf32), which was firstly identified in a
cDNA library prepared from fetal liver mRNA (acces-
sion number: AB024705), maps to chromosome 3p25.3.
LOC51066 (C3orf32) includes at least three open read-
ing frames (ORF) which are assumed to encode various
translation products probably with different functional
relevance (for reference see relevant NCBI and EMBL
data bases; accession numbers: Q9Y2M2, BAA76932,
NM_015931, NP_057015). However, a translation pro-
duct of about 39 kDa with wide tissue distribution
including human small intestine is favored, but experi-
mental evidence to verify existence of the protein is not
given up to now.
Sequence analysis of the putative human fls485 pro-
tein revealed conserved DnaJ-class molecular chaperone
domains [11]. In Escherichia coli DnaJ is a homodimeric
molecule composed of four successive N-terminal
regions representing functional domains: a J-domain
(initial 73 amino acids of the Escherichia coli protein;
HPD motif in loop regions), a glycine- and phenylala-
nine-rich G/F domain (residues 77-107), a central zinc-
binding cysteine-rich CR-domain (residues 144-200),
and a less conserved C-terminal domain [12,13]. DnaJ, a
primary Hsp40 homologue, interacts specifically with
DnaK, a Hsp70 protein, to participate in cellular pro-
cesses like protein folding, transport, and degradation of
misfolded proteins [14-16]. Sequence alignments of
fls485 (NP_057015) revealed at least four zinc finger-like
domain repeats of -CXXCXGXG-encoded by exons 4, 5,
and 6. Exons 5 and 6 additionally encoded truncated
motifs of -CXXCXG-. In general, -CXXC-sequences are
assumed to be specific motifs for the thiol-/disulfide
active sites of oxidoreductase members of the thiore-
doxin super-family [17]. fls485 is in discussion to be a
candidate tumour suppressor gene, because it is mapped
close to the uveal melanoma susceptibility locus UVM2
at 3p25 [18].
At present, fls485 protein synthesis is not shown in
human tissues, and functional investigations concerning
fls485 proteins are not published. The aim of the pre-
sent study was to analyze expression of the fls485 gene
and synthesis of respective proteins in human small
intestinal mucosa of normal or disturbed CVA.
Methods
Tissues and cell culture
Normal small and large intestinal mucosa (n = 12; mean
age, 68 years; range, 43 to 83 years; gender, m = 7, w = 5)
mechanically dissected from the underlying tissues in
surgical resections for sporadic cancer of the ascending
colon were used for basic molecular and in situ analyses.
Additionally, biopsies of normal small intestinal mucosa
(n = 28; mean age, 40 years; range, 12 to 74 years; gender,
m = 10, w = 18) as well as of small intestinal mucosa
affected with celiac disease (n = 14; mean age, 58 years;
range, 26 to 79 years; gender, m = 9, w = 5) were investi-
gated. Tissues with celiac disease were designated as
Marsh I (n = 2), Marsh II (n = 4), or Marsh III (total
n = 8; IIIa, n = 2; IIIb, n = 4; IIIc, n = 2) according to
Marsh-classification and criteria of the European Society
of Pediatric Gastroenterology and Nutrition (ESPGAN)
[4,5]. The use of human tissues was approved by each
patient and the local ethics committee of the RWTH
Aachen University. All diagnoses were established by
conventional clinical and histological criteria [4,5].
Generation of mouse monoclonal antibodies
The human fls485 sequence (bp 543 - 1017) was ampli-
fied by PCR as a BamHI/HindIII fragment (from the
RZPD clone ID IRAUp969F10104D6) and cloned into
the IPTG inducible expression vector pQE-8 (Qiagen,
Hilden, Germany) resulting in a fusion protein with a
C-terminal hexa-histidine tagg. The protein was purified
using Ni-chelate chromatography (Qiagen). The urea
fraction of the purified protein was used to immunize
male mice employing standard procedures. The first
injections of the protein were in Freund’sc o m p l e t e
adjuvant (Sigma, Deisenhofen, Germany). Subsequent
injections were administered with antigen dissolved in
PBS. Monoclonal antibodies were raised essential
according to the method described [19]. Screening of
the hybridomas for antibody production was performed
using ELISA and immunoblot techniques following stan-
dard protocols [20].
Cloning and expression of tagged fls485
A 474 bp fls485 fragment named fls485
158 was amplified
from the pReceiver-MO2-fls485 distributed by the
RZPD and cloned into HindIII - XhoI sides of pEGFP-
C1 (Invitrogen) controlled by sequencing on both
strands. Transient transfections were carried out in 3T3
cells with lipofectamine 2000 as recommended by the
manufacturer (Invitrogen). Efficiency of transient trans-
fections was evaluated with a Nikon fluorescence micro-
s c o p ea n da p p r o p r i a t es o f t w are (Nikon, Düsseldorf,
Germany).
Preparation of RNA and protein
Small or large intestinal mucosa specimens dissected
from surgical resections or small intestinal mucosal
biopsies were homogenized in TriReagent (Sigma). RNA
and protein were simultaneously extracted according to
Chomczynski’s method [21]. Proteins were assayed by
the BioRad approach (BioRad, München, Germany).
Final protein preparations in Laemmli buffer were
stored at -20°C until use.
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3 μg of DNase-digested total RNA was used for oligo
(dT) primed first strand cDNA synthesis with Super-
Script amplification (Invitrogen) following manufac-
turer’s suggestions. Reverse transcription was followed
by RNase H digestion step (20 min at 37°C). Control
experiments included substitution of the enzyme reverse
transcriptase by distilled water and transcription of a
commercially provided RNA (50 ng). PCR analyses were
performed in the LightCycler system (Roche-Diagnos-
tics, Mannheim, Germany) following routine protocols
[10]. Briefly, respective cDNAs were amplified using a
well adapted set of primers corresponding to the coding
sequences of human fls485 (primer pair I, exon 1
through exon 3: 5’-GAG ACC TCG TCA TCC AGG
AG-3’,5 ’-TTG ACC AGT GAC GAG TGA GG-3’;p r i -
mer pair II, exon 8 through exon 9: 5’-TGC AGC AGC
GCC AGA C-3’,5 ’-ACA GCA ATA CCG CTC AGG
AT-3’). PCR was performed in 20 μl aliquots consisting
o f2m MM g C l 2, 0.5 pM each primer, 2 μlS Y B Rg r e e n
mix, and 2 μl cDNA [45 × (95°C; 10 s/60°C; 15 s/72°C;
10 s)]. For amplification of villin transcripts the follow-
ing set of primers were used: 5’-AGC TTA TCA AGC
CGT CAT CC-3’,5 ’-CCC GGT CTC CAA GTT GTT
AG-3’. The PCR conditions were identical to fls485
PCRs. Amplicon integrity was evaluated by fluorescence
reading, melting step, and 2% agarose ethidium bromide
gels. Quantification of mRNA expression levels between
groups was performed when probes were normalized to
the GAPDH content. Differences between groups were
evaluated with the two-paired t-test.
mRNA in situ hybridization
A fragment of human fls485 (NM_015931; 544-1017)
was amplified by RT-PCR and cloned into pBluescript II
KS (-) (Invitrogen, Karlsruhe, Germany). Orientation of
the inserts was determinedb ys e q u e n c i n g .P l a s m i d s
were restricted with BamH1 or HindIII and then tran-
scribed with T3 (antisense) or T7 (sense) RNA polymer-
ase. Dewaxed small intestinal tissue sections were
proteinase K treated (Roche-Diagnostics; 8 μg/ml in
PBS; 30 min at 37°C), acetylated, and then incubated
with Dig-labeled riboprobes (7 or 14 ng/μl) at 47°C
overnight. AP-labeled anti-Dig antibodies and appropri-
ate chromogens were applied for visualization.
Western blot analysis
Proteins in Laemmli sample buffer were resolved by
SDS-PAGE (10%) and transferred to PVDF Immobilon-
P membrane. For molecular weight estimation of pro-
teins, Rainbow molecular weight marker was used fol-
lowing manufacturer’s suggestions (Amersham
Pharmacia Biotech, Little Chalfont, England). The fol-
lowing antibodies were used: mouse anti-human beta-
actin (0.4 μg/ml; Santa Cruz Biotechnology, Santa Cruz,
USA), mouse anti-human fls485 (clone #7 or clone #10
and subclones), and secondary HRP-conjugated antibo-
dies (1:10,000; Santa Cruz Biotechnology, Santa Cruz,
USA). His- or EGFP-taggs were detected with antibodies
directed against 6xHis (R&D Systems, Wiesbaden, Ger-
many) or EGFP (OpenBiosystems, Huntsville, USA). The
ECL substrate (Amersham) was applied following manu-
facturer’s recommendations. Negative controls included
blots in which the primary antibody was omitted.
Immunohistochemistry
Sections of paraffin-embedded small intestinal tissues or
cryo-conserved specimens were used following routine
protocols [10]. Briefly, paraffin-embedded sections were
dewaxed and incubated in citrate buffer pH 6.0 for 30
min at 95°C. The cryo-sections were fixed with acetone
for 10 min at -20°C. Afterwards sections were washed in
PBS, treated with 1% normal serum, and then incubated
with the primary anti-fls485 antibody for 1 h at room
temperature in a moist chamber. Sections were then
washed in PBS and incubated for 30 min with the sec-
ondary biotinylated goat anti-mouse IgA antibody
(DAKO, Glostrup, Denmark) diluted 1:200 in PBS. The
ABC detection kit (VECTOR, Burlingame, USA) and
DAB (DAKO) as well as Cy2-, Cy3- (both Dianova,
Hamburg, Germany) or FITC-fluorochromes (Jackson
ImmunoResearch, Baltimore, USA) were used as sug-
gested by the providers. In negative controls sections
were similarly processed but the appropriate normal
serum was used or the primary antibody had been
totally omitted. For semi-quantitative evaluation of
immunostainings a value representing the product of
staining intensity (1 through 3) and the number of spe-
cifically immunostained cells (0 = negative, 1 = < 10%,
2 = 10 - 50%, 3 = 51 - 80%, 4 = > 80%) were used. Dif-
ferences between groups were evaluated with two-paired
t-test.
Cell culture and transfection
For cell culture experiments Rko cells (ATCC: CRL-
2577), Lovo cells (ATCC: CCL-229), and CaCo2 cells
(ATCC: HTB-37), all human colon cancer cell lines, or
3T3 fibroblasts (ATCC: CCL-92) were used. All cells
were maintained in 5% CO2 atmosphere at 37°C. Rko
cells were maintained in culture with RPMI1640,
whereas DMEM with 2 mM L-glutamine was used for
Lovo and 3T3 cells. CaCo2 cells were cultured in
EMEM supplemented with 2 mM L-glutamine. Media
were supplemented with 5 - 10% fetal bovine serum. All
transfections were performed with lipofectamine 2000
(Invitrogen) following manufacturer’s recommendations.
For functional experiments, CaCo2 cells were seeded
with a cell number of 10
4/cm
2 (group I: low cell
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5/cm
2 (group II: high cell number). Cell
growth and maturation were controlled by microscopy
and villin mRNA expression. Villin gene expression has
been demonstrated as valuable biomarker for differentia-
tion of enterocytes and CaCo2 cells [22-24]. Confluence
of cells was found in group II cells after a time period
of three days. All cells were harvested, total RNA was
prepared, and fls485 as well as villin RT-PCR were per-
formed as described above. The results from three sepa-
rate experiments were used for statistical analysis.
Results
Establishment and characterization of monoclonal
antibodies recognizing fls485
Immunization of mice, cellular fusion, and subsequent
purification revealed a panel of IgG ELISA positive
mAbs recognizing epitopes within the target-peptide of
fls485. Positive clones #7 and #10 were ELISA-detected
and a panel of subclones #7/1, #7/2, and #10/15 was
established. Specificity against fls485 was corroborated
by expression of the fusion protein EGFP-fls485
158 in
3T3 cells. Western blotting of 3T3 transient EGFP-
fls485
158 transfectants and probing of membranes with
#7 or #10 clones/subclones revealed the fusion protein
(approx. 61 kDa) which was additionally recognized
with antibodies against the EGFP tagg (Figure 1A). The
data were further substantiated by fluorescence imaging
of EGFP and fls485/fls485
158 in CaCo2 transient trans-
fectants (Figures 1B-H).
fls485 mRNA and proteins are found in intestinal mucosa
In RT-PCRs, fls485 mRNA was detectable with primer
pair I and II in all normal small intestinal mucosa
probes investigated (n = 31; data not shown). These
data were substantiated with mRNA in situ hybridiza-
tion showing enterocytes and chromaffine cells as
important sources of fls485 mRNA (Figure 2A,B). Along
the CVA, fls485 mRNA was preferentially detectable in
lower parts. An increasing mRNA gradient as suggested
by previous work [10] was not detectable. Additional
Figure 1 Characterization of anti-fls485 antibodies. Detection of chimeric EGFP-fls485
158 protein in transfected 3T3 (A: Western blot) or
CaCo2 cells (B-H: immunofluorescence) with different anti-fls485 antibodies. (A) Western blots of EGFP-fls485
158 expressed in 3T3 cells incubated
with antibodies directed against fls485
158 clone/subclone #7 (left) or clone/subclone #10 (middle). Endogenous fls485 expression by 3T3 cells is
detectable as a signal about 55 kDa when incubated with the anti-fls485 clones. One additional signal about 35 kDa is exclusively found when
clone/subclone #10 is used. EGFP-fls485
158 expression in 3T3 transfectants was additionally visualized with anti-EGFP antibodies as control (right).
(B-D) Immunofluorescence of EGFP-fls485
158 protein in transfected CaCo2 cells incubated with clone/subclone #7, secondary antibody Cy3-
labeled (B), anti-EGFP, secondary antibody FITC-labeled (C), and overlay (D). (E-G) Immunofluorescence of EGFP-fls485
158 protein in transfected
CaCo2 cells incubated with clone/subclone #10, secondary antibody Cy3-labeled (E), anti-EGFP, secondary antibody FITC-labeled (F), and overlay
(G). (H) Negative control; EGFP-fls485
158 transfected CaCo2 cells after incubation with all secondary antibodies.
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Page 4 of 9Figure 2 Characterization of fls485 expression in intestinal mucosa.f l s 4 8 5e x p r e s s i o ni nh u m a ni n t e s t i n a lm u c o s aw i t hm R N Ain situ
hybridization (A and B), Western blot analysis (C and D), or immunohistochemistry (E and F). (A) Distribution of fls485 mRNA in human small
intestinal mucosa (antisense riboprobe). The arrows mark strong mRNA accumulation in putative chromaffin cells (original magnification approx.
× 200). (B) Serial section of (A) incubated with fls485 sense riboprobe (original magnification approx. × 200). (C) Blotted protein lysates from
human small and large intestinal mucosa as well as Rko and Lovo cells after incubation with clone #7. (D) Blotted lysates as shown in (C) probed
with clone #10. (E) fls485 protein is found with an increasing gradient along the CVA (clone #10) (original magnification approx. × 200).
Chromaffin cells are marked by arrows. Note some interstitial cells are stained. (F) Strong fls485 immunostaining is found in a chromaffin cell
(arrow), whereas Paneth cells (arrowheads) are only slightly or not stained (clone #10) (original magnification approx. × 400).
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probably lymphocytes.
In order to investigate the fls485 protein pattern, Wes-
tern blot analysis of human small and large intestinal
mucosa as well as of two intestinal cell lines, Rko and
Lovo, was performed. PVDF membranes were probed
with the newly established anti-fls485 antibodies (Figure
2C,D). The different subclones of #7 and #10 founders
regularly revealed a signal about 55 kDa. In addition, a
second strong signal (approx. 35 kDa) was found with
clone #10 and subclone #10/15 in preparations of small
intestinal mucosa and Lovo, but not in Rko cells. How-
ever, the 35 kDa signal was not detectable with #7
clones. Interestingly, a difference in the distribution of
the two protein signals was revealed when comparing
small and large intestinal mucosa. The 55 kDa molecule
was preferentially found in preparations from large
intestinal mucosa, whereas the small intestinal mucosa
was dominated by the protein with lower molecular
weight. In addition, the protein distribution pattern of
large intestinal mucosa was similar to the findings with
Lovo and Rko cells (Figure 2C,D)
Immunostaining against fls485 proteins with #7 or #10
clones/subclones revealed protein localization in the sur-
face lining epithelium occasionally with a slightly
increasing gradient from crypts to villi (Figure 2E). In
enterocytes from small and large intestine, the protein
displayed a constant cytoplasmic distribution without
any visible co-localization to cellular membranes. The
surface-lining enterocytes were intermingled with some
cells strongly immunostained for fls485 protein and
morphologically characterized by an apical nucleus and
baso-lateral cytoplasm with infranuclear granules char-
acteristic for chromaffin cells (Figure 2F). Anti-fls485
immunostaining of Paneth cells was very weak or not
detectable, whereas some lamina propria cells preferen-
tial lymphocytes were positive. Results from immunos-
tainings did not differ between #7 and #10 subclones.
Impaired expression of fls485 in celiac disease
In order to prove a putative link between CVA behavior
and fls485 expression, small intestinal mucosa affected
with CVA disturbing celiac disease was investigated.
Using qRT-PCR (primer pair I and II) fls485 mRNA
expression was significantly decreased in mucosal biop-
sies affected with celiac disease Marsh IIIa-c (n = 8)
when compared with normal controls (n = 28) (primer
pair I: 7.2 fold, p < 0.0001; primer pair II: 8.7 fold, p <
0.0001). In celiac diseased biopsies smaller than Marsh
IIIa stages (n = 6) fls485 mRNA levels were similar to
controls (primer pair I: 1.3 fold, p > 0.05; primer pair II:
1.3 fold, p > 0.05) (Figure 3A,B). RT-PCR findings were
in line with anti-fls485 immunostainings of celiac dis-
eased tissues (Figure 3C,D) when compared with normal
mucosa (Figure 2E). Diminished fls485 immunostaining
with clone #7 and #10 or appropriate subclones was
found in small intestinal biopsies with different stages of
villus atrophy (Marsh IIIa-c). In such specimens, a com-
pensatory fls485 protein increase in epithelia lining elon-
gated crypts was never visible. However, the differences
in fls485 tissue staining were not significant using a
semi-quantitative scoring system with fls485 staining
intensity and number of anti-fls485-stained cells as vari-
ables (p > 0.05).
T h er o l eo ff l s 4 8 5i nc e l l u l a rm a t u r a t i o nw a sf u r t h e r
addressed in a functional CaCo2 assay. Low and high
density cultures of CaCo2 cells have been established as
a well accepted model of cellular maturation reflecting
the molecular events along the CVA [24]. In order to
investigate fls485 expression in different stages of cellu-
lar maturation, CaCo2 cells were cultured in low or
high density. In this experimental setting maturation of
CaCo2 cells was paralleled by an increase of fls485
mRNA (primer pair I, p < 0.05) (Figure 3E,F).
Discussion
Proliferation and differentiation of epithelial cells are
generally associated with complex changes in gene
expression and protein synthesis. Investigation of the
molecular mechanisms involved is facilitated by descrip-
tive studies of high-turnover epithelial differentiation as
found in the CVA of human small intestinal mucosa. As
recently shown, maturation of human enterocytes along
the CVA is associated with differential expression of at
least 778 genes including fls485 [10]. The gene fls485
(LOC51066) includes at least three ORFs and is sug-
gested to encode a putative chaperon protein of approx.
39 kDa (accession numbers: Q9Y2M2, BAA76932) of
unknown intestinal tissue distribution and function. We
aimed to analyze distribution of fls485 mRNA and pro-
tein in enterocytes along the CVA of normal intestinal
mucosa and in celiac disease which is characterized by
sequential CVA destruction. In order to elucidate fls485
expression, fls485 tissue distribution, and putative func-
tional impacts a panel of monoclonal antibodies was
generated in mice using a fls485 core peptide. In a pri-
mary setting of our mice immunization experiments,
two epitopes included in the fls485
49-206 sequence
(EKKLLHFIQLV and KRKAKQSRR), both predicted to
bind MHC molecules with high affinity, were separately
applied. Using these peptides in mice, however, the
experiments failed to generate useful monoclonal anti-
bodies. However, in a second approach, powerful antibo-
dies were established by using the fls485 core peptide.
The so generated anti-fls485 antibodies provided differ-
ent application options, including immunostaining and
Western blotting. The disadvantage of this procedure,
the unknown protein binding site of the antibodies, was
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Page 6 of 9Figure 3 Impaired fls485 expression in celiac disease. fls485 expression is impaired in human small intestinal mucosa affected with celiac
disease classified Marsh IIIa-c when compared with normal mucosal specimens (controls). (A) fls485 mRNA expression in small intestinal mucosa
detected with primer pair I. (B) fls485 mRNA expression detected with primer pair II in the identical probes as shown in (A). (C) Anti-fls485
immunohistochemistry (clone #7/2) of intestinal mucosa classified Marsh IIIb (original magnification approx. × 200). (D) Serial tissue section of (C)
incubated with normal serum as negative control (original magnification approx. × 200). (E) Morphological aspects of CaCo2 cells cultured with
low or high cellular density (original magnification approx. × 200). (F) fls485 expression normalized to GAPDH is increased in high density CaCo2
cell cultures (primer pair I, p < 0.05).
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comparison of staining results, and fls485 expression
profiling as subsequently detailed.
Characterization of selected clones #7, #10, and depen-
dent subclones was performed with a panel of well-
adapted techniques. Firstly, ELISA screening against KLH
or BSA identified founder clones #7 and #10. Secondly,
transient transfections of 3T3 fibroblasts with a EGFP-
fls485 construct resulted in expression of the EGFP-
fls485
158 fusion protein, which was characterized with
Western blotting and detection of the EGFP-tagg (anti-
EGFP antibodies) or the fls485
158 protein (anti-fls485
antibodies #7 and #10 as well as subclones). Thirdly, co-
localization of EGFP and fls485 immunosignaling was
found in EGFP-fls485
158 3T3 and CaCo2 transfectants.
Fourthly, immunostainings of sectioned paraffin-
embedded normal human small intestinal mucosa with
#7, #10 or subclones revealed an overlap with the fls485
mRNA in situ hybridization pattern. Fifthly, anti-fls485
immunostaining was constantly found intracytoplasmic
which confirms the assumption of fls485 being a soluble
intracytoplasmic molecule as predicted by its amino acid
sequence. Sixthly, corresponding to three ORFs of the
fls485 gene and putative posttranslational protein modifi-
cations a protein of the predicted weight (approx. 35
kDa) and at least one additional protein (approx. 55 kDa)
were repeatedly found in Western blotting. Our attempts
to further purify the proteins from small intestinal enter-
ocytes or cell lines were hampered by technical obstacles
probably due to posttranslational protein modifications.
In continuation of these experiments, we will establish
stable fls485 transfectants and synthesize recombinant
fls485 protein, which are both of high interest in bio-
chemical and prospective functional fls485 analysis.
Immunostainings of fls485 protein revealed an
increasing gradient from crypts to villi as anticipated
from a previous mRNA expression study [10]. Using
anti-fls485 mRNA in situ hybridization, the increasing
fls485 mRNA gradient was not reproducible. We specu-
late that the phenomenon could be due to existence of
different fls485 mRNA species which are incompletely
hybridized with the riboprobes in use. However, current
riboprobes included a putative overlapping sequence of
respective mRNA species deriving from the three fls485
ORFs. In order to clarify this issue a detailed fls485
mRNA expression study using laser microdissected
enterocytes from different CVA locations and mRNA in
situ hybridization experiments with additional ribop-
robes is conceived. Another possibility for aberrant
fls485 mRNA expression along the CVA could be a
post-transcriptional control of fls485 protein synthesis.
However, at present we have no data to further sub-
s t a n t i a t et h i sa s s u m p t i o n .A saf i n a lp o i n ti th a st ob e
noted here is that asymmetric distribution of mRNA
and protein species along the CVA is possible and has
been already demonstrated for other genes [23].
Our study gives evidence that fls485 mRNA and pro-
teins are physiologically found in human intestinal
mucosa as well as in several cell lines (including Lovo,
Rko, CaCo2, HeLa, 3T3, HCT116, Capan1). However, at
present there are no data available concerning the func-
tional relevance of the fls485 protein and its different
isoforms. We do hypothesize from the fls485 amino acid
sequence consisting of at least four zinc finger-like
domain repeats of -CXXCXGXG- (NP_057015) that
fls485 could be a chaperone with thiol-disulfide oxidore-
ductase activity. Such motifs are additionally found in
redox-regulated molecular chaperones such as Hsp33
[12,25], a protective molecule which might be directly
involved in bacterial colonization of the intestine [26].
Bacterial overgrowth [27] and increased oxidative stress
[28] are frequently found in patients suffering from
celiac disease. It could be hypothesized that an impaired
expression of the putative chaperone fls485 might be
involved in the pathogenesis of such complications.
Indeed, our present studies revealed impaired fls485
expression in human small intestinal mucosa affected
with celiac disease Marsh IIIa-c, whereas no significant
difference was detectable between diseased mucosal spe-
cimens classified lower than Marsh IIIa and normal
intestinal mucosa (controls). This observation and our
functional findings from CaCo2 cells argue for an inter-
dependence of enterocyte differentiation along the CVA
and fls485 expression. As stated above, the use of fls485
transfectants and recombinant fls485 protein as well as
m u c o s a lt i s s u ec u l t u r e si ss uggested as promising func-
tional approach to further investigate the phenomena.
Conclusions
Here we show experimental evidence for fls485 mRNA
expression and protein synthesis in human intestinal
mucosa and impaired expression in celiac disease. We
assume from fls485 gene structure, amino acid motifs,
and Western blot analysis that at least two fls485 pro-
teins might exist which could probably be involved in
differentiation of the CVA. Our findings provide a fra-
mework for guiding further experiments to clarify con-
sequences of aberrant fls485 expression in celiac-
diseased intestinal tissues.
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